RemeGen Co., Ltd. (HKG:9995)

Market Cap	52.82B
Revenue (ttm)	2.27B
Net Income (ttm)	-1.25B
Shares Out	555.84M
EPS (ttm)	-2.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,051,096
Average Volume	6,767,726
Open	89.50
Previous Close	88.95
Day's Range	85.60 - 89.50
52-Week Range	11.52 - 126.60
Beta	0.87
RSI	41.79
Earnings Date	Oct 30, 2025

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 2,999
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial numbers in CNY